Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Chicago, Illinois

This page shows live ClinicalTrials.gov search results for Chicago, Illinois, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 5:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
17822
Shown on this page
12
Current sort
Recently updated
Location scope
Chicago, IL
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Chicago, Illinois. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 241–252 of 17,822 matching trials in Chicago, IL.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Chicago

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Recruiting Phase 3 Interventional

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

NCT07388524
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma
Interventions
Atezolizumab, Atezolizumab and Recombinant Human Hyaluronidase, Biospecimen Collection, Computed Tomography, Patient Observation
Biological · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2032
U.S. locations
145
States / cities
Anaheim, California • Baldwin Park, California • Bellflower, California + 121 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Active, not recruiting Phase 2 Interventional

A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD)

NCT06285643
View directory record Official record
Conditions
Parkinson Disease
Interventions
AAV2-GDNF gene therapy, control surgery
Drug · Procedure
Lead sponsor
AskBio Inc
Industry
Eligibility
45 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
34
States / cities
Phoenix, Arizona • Irvine, California • Loma Linda, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Recruiting Phase 2Phase 3 Interventional

Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

NCT07570654
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, PTSD, PTSD Symptoms, PTSD, Post Traumatic Stress Disorder
Interventions
COMP360 psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
15
States / cities
Tucson, Arizona • Irvine, California • Los Angeles, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Terminated Phase 2 Interventional Results available

A Study of K-645 in the Treatment of Multiple Migraine Attacks

NCT07116499
View directory record Official record
Conditions
Migraine
Interventions
K-645 100 mg, K-645 10 mg, Placebo
Drug
Lead sponsor
TriGemX Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
18
States / cities
Oceanside, California • Atlanta, Georgia • Stockbridge, Georgia + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Recruiting Not applicable Interventional

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

NCT07214532
View directory record Official record
Conditions
Breast Neoplasms, Carcinoma, Ductal, Breast, Receptors, Estrogen (for ER-positive Requirement)
Interventions
ctDNA-Guided Treatment Strategy
Device
Lead sponsor
Natera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Active, not recruiting Not applicable Interventional

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

NCT06310031
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Heart Failure
Interventions
BrioVAD System, HeartMate 3
Device
Lead sponsor
BrioHealth Solutions, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
780 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Active, not recruiting No phase listed Observational

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

NCT06078553
View directory record Official record
Conditions
Congenital Myasthenic Syndrome
Interventions
Not listed
Lead sponsor
argenx
Industry
Eligibility
2 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Sacramento, California • Chicago, Illinois • O'Fallon, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Recruiting Phase 2 Interventional

Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System

NCT07042295
View directory record Official record
Conditions
Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma
Interventions
Amivantamab and Recombinant Human Hyaluronidase, Biospecimen Collection, Cetuximab, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
59
States / cities
Birmingham, Alabama • Gilbert, Arizona • La Jolla, California + 50 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain

NCT05986292
View directory record Official record
Conditions
Osteoarthritis, Knee, Diabetic Neuropathic Pain, Chronic Low-back Pain
Interventions
LY3016859 ISA, LY3556050 ISA, LY3526318 ISA, LY3857210 ISA, Placebo Oral, Placebo, LY4065967 ISA
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
62
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Active, not recruiting Phase 3 Interventional

A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.

NCT05739383
View directory record Official record
Conditions
Primary Prevention of Atherosclerotic Cardiovascular Disease
Interventions
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, Placebo in 1.5ml
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 79 Years
Enrollment
14,012 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
241
States / cities
Birmingham, Alabama • Fairhope, Alabama • Foley, Alabama + 187 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Recruiting Phase 2 Interventional

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

NCT04918186
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Durvalumab, BA3011, BA3021, ENB003, Toripalimab
Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST
Recruiting Phase 3 Interventional

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

NCT06541704
View directory record Official record
Conditions
Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Interventions
Pozelimab, Cemdisiran, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years to 85 Years
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
160
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 126 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2026 · Synced Nov 10, 2026, 5:51 PM EST